ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1336

Unique Role for miR429 in RA and Acute Model of Arthritis

Jonatan Hervoso1, W. Alexander Stinson1, Yuxuan Du2, Sarah Arwani1, Ellen Cealey1, David A. Fox1 and M. Asif Amin1, 1Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, 2Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, MI

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cell Migration, Inflammatory arthritis and rheumatoid arthritis (RA), MicroRNA

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Animal Models Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is characterized by inflammation and subsequent infiltration of peripheral blood monocytes (MNs) into the synovial tissue (ST). Micro (mi)RNAs are non-coding RNAs which regulate many physiological and pathological functions at the posttranscriptional level. We performed miRNA PCR array and found a panel of miRNAs, including miR429, were highly expressed in response to TNF-α in MNs. Hence we examined the contribution miR429 and one of its target genes, PAK2, in MN chemotaxis and acute inflammatory arthritis.

Methods: The expression of miR429 in RA and NL MNs was assessed via quantitative (q)PCR. RA MNs and RA fibroblast-like synoviocytes (FLS) were transfected with inhibitors and mimics of miR429 for 24 hours. Then these cells were stimulated with TNF-α for 25 minutes to determine phosphorylation of signaling molecules by Western blotting. We transfected U937 cells, a human leukemic MN lymphoma cell line, and NL MNs with miR429 mimics and inhibitors and performed chemotaxis. To investigate the role of miR429 in acute inflammation, miR429 shRNA or control shRNA were packaged into lentivirus and injected into mouse knees 30 minutes prior to administration of TNF-α or Zymosan. Mouse knee circumference was measured before injections and again 24 hours later. Following euthanasia, knees were harvested for immunofluorescence staining or homogenized for analysis of inflammatory cytokines.

Results: Non-stimulated RA MNs had a 2.6 fold increase in miR429 expression compared to non-stimulated Normal (NL) MNs by qPCR. We also found that miR429 is inducible, TNF-α induced significantly higher miR429 expression in NL MNs compared to non-stimulated MNs. With regards to MN migration, inhibition of miR429 decreased migration of U937 cells and MNs in response to MCP1/CCL2, suggesting a role for miR429 in MN migration. TNF-α upregulation of phospho-Erk, -JNK and -NFkB was decreased when RA MNs were transfected with miR429 inhibitor. Similarly, a decrease of TNF-α induced phospho-Erk, -JNK and -NFkB was observed in RA FLS. Furthermore we also determined that a miR429 target gene, PAK2, was downregulated when miR429 was inhibited in RA MNs and RA FLS. Additionally, TNF-α and Zymosan treated mouse knee swelling was significantly reduced in mice injected with miR429 inhibitor compared to control, indicating that miR429 is critical to arthritis development in vivo. We also found decreased ingress of leukocytes into mouse knee cryosections treated with miR429 inhibitor.

Conclusion: miR429 expression is increased with TNF-α stimulation and has higher levels in RA compared to NL MNs. miR429 plays an essential role in the migration of MNs and also regulates phosphorylation of signaling molecules and PAK2 transcription factor. Additionally mice treated with miR429 inhibitor showed decreased inflammation indicating the importance of miR429 in acute inflammation and MN recruitment. This data suggests that miR429 may be a therapeutic target in MN dependent diseases.


Disclosure: J. Hervoso, None; W. A. Stinson, None; Y. Du, None; S. Arwani, None; E. Cealey, None; D. A. Fox, None; M. A. Amin, None.

To cite this abstract in AMA style:

Hervoso J, Stinson WA, Du Y, Arwani S, Cealey E, Fox DA, Amin MA. Unique Role for miR429 in RA and Acute Model of Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/unique-role-for-mir429-in-ra-and-acute-model-of-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unique-role-for-mir429-in-ra-and-acute-model-of-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology